

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please substitute the following claim 37 for the pending claim 37:

37. (Thrice Amended) A pharmaceutical composition comprising a nucleic acid encoding a nitric oxide synthase gene operably linked to a pulmonary tissue specific expression control element, an adenoviral vector and a pharmaceutically acceptable carrier vehicle, wherein said composition is in an aerosolized form.